Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Overview 10 Therapeutics Development 11 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Stage of Development 11 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Therapy Area 12 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Indication 13 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Companies 17 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Universities/Institutes 23 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Therapeutics Assessment 25 Assessment by Monotherapy/Combination Products 25 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Companies Involved in Therapeutics Development 32 Advaxis, Inc. 32 American Gene Technologies International Inc. 33 Aprea AB 34 Cellceutix Corporation 35 Critical Outcome Technologies Inc. 36 Eleos Inc. 37 ORCA Therapeutics B.V. 38 OSE Pharma SA 39 PCI Biotech Holding ASA 40 Quark Pharmaceuticals, Inc. 41 Stemline Therapeutics, Inc. 42 Shenzen SiBiono GeneTech Co., Ltd. 43 SK Biopharmaceuticals Co., Ltd. 44 Tara Immuno-Oncology Therapeutics LLC 45 Z53 Therapeutics, LLC 46 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Drug Profiles 47 Adxs-LmddA159 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AG-1101 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 APR-017 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 APR-246 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ATRN-502 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 cenersen sodium - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 contusugene ladenovec - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 COTI-2 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 D-12PGJ3 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Gene Therapy to Activate p53 for Oncology - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 KM-3174 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 MHY-449 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 MJ-05 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 MX-225 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 N-2 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Oncolytic Viruses to Activate p53 for Oncology - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 OSE-2101 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 p28 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 QPAL-1 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 QPI-1002 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Recombinant Protein to Activate p53 for Oncology - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 SGT-53 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 SL-801 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecule to Activate p53 for Cancer - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Small Molecules to Activate p53 for Cancer and Viral Infections - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Small Molecules to Activate p53 for Melanoma - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 ZMC-1 - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Dormant Projects 104 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Discontinued Products 110 Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Featured News & Press Releases 111 Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers 111 Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 111 Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 112 Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients 113 Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer 114 Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 114 Feb 16, 2016: Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors 115 Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer 115 Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer 116 Jan 22, 2016: Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer 117 Appendix 118 Methodology 118 Coverage 118 Secondary Research 118 Primary Research 118 Expert Panel Validation 118 Contact Us 118 Disclaimer 119

List of Tables Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Development by Companies, H1 2016 (Contd..2) 20 Products under Development by Companies, H1 2016 (Contd..3) 21 Products under Development by Companies, H1 2016 (Contd..4) 22 Number of Products under Investigation by Universities/Institutes, H1 2016 23 Products under Investigation by Universities/Institutes, H1 2016 24 Assessment by Monotherapy/Combination Products, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Pipeline by Advaxis, Inc., H1 2016 32 Pipeline by American Gene Technologies International Inc., H1 2016 33 Pipeline by Aprea AB, H1 2016 34 Pipeline by Cellceutix Corporation, H1 2016 35 Pipeline by Critical Outcome Technologies Inc., H1 2016 36 Pipeline by Eleos Inc., H1 2016 37 Pipeline by ORCA Therapeutics B.V., H1 2016 38 Pipeline by OSE Pharma SA, H1 2016 39 Pipeline by PCI Biotech Holding ASA, H1 2016 40 Pipeline by Quark Pharmaceuticals, Inc., H1 2016 41 Pipeline by Stemline Therapeutics, Inc., H1 2016 42 Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 43 Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 44 Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 45 Pipeline by Z53 Therapeutics, LLC, H1 2016 46 Dormant Projects, H1 2016 104 Dormant Projects (Contd..1), H1 2016 105 Dormant Projects (Contd..2), H1 2016 106 Dormant Projects (Contd..3), H1 2016 107 Dormant Projects (Contd..4), H1 2016 108 Dormant Projects (Contd..5), H1 2016 109 Discontinued Products, H1 2016 110 List of Figures Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Top 10 Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 25 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 30

Advaxis, Inc. American Gene Technologies International Inc. Aprea AB Cellceutix Corporation Critical Outcome Technologies Inc. Eleos Inc. ORCA Therapeutics B.V. OSE Pharma SA PCI Biotech Holding ASA Quark Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Shenzen SiBiono GeneTech Co., Ltd. SK Biopharmaceuticals Co., Ltd. Tara Immuno-Oncology Therapeutics LLC Z53 Therapeutics, LLC